CEO
Gerald McMahon
Employees
95
Industry
Biological Product (except Diagnostic) Manufacturing
harpoon therapeutics is a pre-clinical stage biotechnology company co-founded by patrick bauerle, a pioneer in t-cell engagement, and luke evnin (mpm capital) in 2015 to develop and commercialize a novel class of t cell recruiting antibodies engage a patient’s own immune cells to fight cancer and other diseases. the world-class team of protein engineers and immunologists at harpoon have built upon the successful development of the bispecific (“bite™ or bispecific t cell engager”) antibody blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. harpoon’s tri-specific t-cell redirection platform -- tritac™ -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, car-t and other t-cell engaging approaches by improving activity against
Loading...
Open
23.00
Mkt cap
865M
Volume
6.4M
High
23.02
P/E Ratio
-15.04
52-wk high
23.21
Low
22.99
Div yield
N/A
52-wk low
3.11
Portfolio Pulse from Benzinga Newsdesk
March 26, 2024 | 2:03 pm
Portfolio Pulse from Vandana Singh
February 01, 2024 | 3:43 pm
Portfolio Pulse from Benzinga Newsdesk
January 16, 2024 | 7:49 pm
Portfolio Pulse from Benzinga Newsdesk
January 08, 2024 | 6:41 pm
Portfolio Pulse from Avi Kapoor
January 08, 2024 | 6:36 pm
Portfolio Pulse from Benzinga Insights
January 08, 2024 | 5:31 pm
Portfolio Pulse from Avi Kapoor
January 08, 2024 | 5:22 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.